Oxidative stress, vascular function and atherosclerosis;Stress oxydant, fonctions vasculaires et athérosclérose

Nutrition Clinique et Metabolisme

Volumn 16, Issue 4, 2002, Pages 260-267

  Bonnefont Rousselot, Dominique ^a   Peynet, Jacqueline ^a   Beaudeux, Jean Louis ^a   Thérond, Patrice ^a   Legrand, Alain ^a   Delattre, Jacques ^a  

^a Faculte de Pharmacie   (France)

Author keywords

Endothelium; Free radicals; Lipoproteins; Oxidation; Second messenger

Indexed keywords

ENDOTHELIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CELL ADHESION; CELL PROLIFERATION; HUMAN; MONOCYTE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM;

EID: 0036945872     PISSN: 09850562     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0985-0562(02)00169-3     Document Type: Review

References (55)

1. Griendling KK, Sorescu D, Lassègue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 2000;20:2175-83.
2. Irani K. Oxidant signaling in vascular cell growth, death, and survival. A review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res 2000;87:179-83.
3. Wolin MS. Interactions of oxidants with vascular signaling systems. Arterioscler Thromb Vasc Biol 2000;20:1430-42.
4. Pearlstein DP, Mir HA, Mungai PT, Hynes KL, Gewertz BL, Schumaker PT. Role of mitochondrial oxidant generation in endothelial cell responses to hypoxia. Arterioscler Thromb Vasc Biol 2002;22:566-73.
5. Warnholtz A, Wendt M, Münzel T. When sleeping beauty turns ugly, Mitochondria in hypoxia. Arterioscler Thromb Vasc Biol 2002;22: 525-7.
6. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000;404: 787-90.
7. Yamagishi SI, Edelstein D, Du XL, Browlee M. Hyperglycemia potentiates collagen-induced platelet activation through mitochondrial superoxide overproduction. Diabetes 2001;50:1491-4.
8. Craven PA, Phillips SL, Melhem MF, Liachenko J, DeRubertis FR. Overexpression of manganese superoxide dismutase suppresses increases in collagen accumulation induced by culture of mesangial cells in high-media glucose. Metabolism 2001;50:1043-8.
9. Jones RD, Hancock JT, Morice AH. NADPH oxidase: A universal sensor? Free Radic Biol Med 2000;29:416-24.
10. Radeke HH, Cross AR, Hancock JT, Jones OT, Nakamura N, Kaever V, et al. Functional expression of NADPH oxydase components (α- and β-subunits of cytochrome b558 and 45-kDa flavoprotein) by intrinsic human glomerular mesangial cells. J Biol Chem 1991;226:21025-9.
11. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 2000;86:494-501.
12. Gölarch A, Brandes RP, Nguyen K, Amidi M, Delghani F, Busse R. A gp91phox containing NAD(P)H oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in arterial wall. Circ Res 2000;87:26-32.
13. Zalba G, San José G, Moreno MU, Fortuño A, Beaumont FJ, Díez J. Oxidative stress in arterial hypertension, Role of NAD(P)H oxidase. Hypertension 2001;38:1395-9.
14. Sorescu D, Szöcs K, Griendling KK. NAD(P)H oxidases and their relevance to atherosclerosis. Trends Cardiovasc Med 2001;11: 124-31.
15. Souza HP, Souza LC, Anastacio VM, Pereira AC, Junqueira LM, Krieger JE, et al. Vascular oxidant stress early after balloon injury: Evidence for increased NADPH oxydoreductase activity. Free Radic Biol Med 2000;28:1232-42.
16. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation, Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-23.
17. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NAD(P)H oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996;271:23317-21.
18. Guzik TJ, West NE, Black E, Mc Donald D, Ratnatunga C, Pillai R, et al. Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxide production in atherosclerosis. Circulation 2000;102:1744-7.
19. Ushio-Kukai M, Alexander RW, Akers M, Yin Q, Fujio Y, Walsh K, et al. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 1999;274:22699-704.
20. Touyz RM, Deschepper C, Park JB, He G, Chen X, Neves MF, et al. Inhibition of mitogen-activated protein/extracellular signal-regulated kinase improves endothelial function and attenuates Ang II-induced contractility of mesenteric resistance arteries from spontaneously hypertensive rats. J Hypertens 2002;20:1127-34.
21. Gorlach A, Diebold I, Schini-Kerth VB, Berchner-Pfannschmidt U, Roth U, Brandes RP, et al. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of p22(phox)-containing NADPH oxidase. Circ Res 2001;89:47-54.
22. Herkert O, Diebold I, Brandes RP, Hess J, Busse R, Gorlach A. NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. Circulation 2002;105:2030-6.
23. Natarajan V, Scribner WM, Al-Hassani M, Vepa S. Reactive oxygen species signaling through regulation of protein tyrosine phosphorylation in endothelial cells. Environ Health Perspect 1998; 106(suppl.5):1205-12.
24. Meyer JW, Schmitt ME. A central role for the endothelial NADPH oxidase in atherosclerosis. FEBS lett 2000;472:1-4.
25. Warnholtz A, Nickerig G, Schultz E, Macharzina R, Brasen JH, Skatchkov M, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system. Circulation 1999;99: 2027-33.
26. Granger DN. Ischemia-reperfusion: Mechanisms of microvascular dysfunction and the influence of risk factors for cardiovascular disease. Microcirculation 1999;6:167-78.
27. Moncada S. Nitric oxide in the vasculature: Physiology and pathophysiology. Ann NY Acad Sci 1997;811:60-7.
28. Birks EJ, Yacoub MH. The role of nitric oxide and cytokines in heart failure. Coron Artery Dis 1997;8:389-402.
29. Geller DA, Billiar TR. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev 1998;17:7-23.
30. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43: 109-42.
31. Devaux C, Varin R, Mulder P, Richard V, Thuillez C. Oxidative stress and endothelial dysfunction in heart failure. Thérapie 2001; 56:575-81.
32. Stamler JS, Hausladen A. Oxidative modifications in nitrosative stress. Nature Struct Biol 1998;5:247-9.
33. Huraux C, Makita T, Kurz S, Yamaguchi K, Szlam F, Tarpey MM, et al. Superoxide production, risk factors, and endothelium-dependent relaxations in human internal mammary arteries. Circulation 1999;99:53-9.
34. De Caterina R. Endothelial dysfunctions: Common denominators in vascular disease. Curr Opin Lipidol 2000;11:9-23.
35. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;388:1042-50.
36. Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Pador TJ, Li J, et al. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 1999;94:959-67.
37. Collins T, Cybulsky MI. NFκB: Pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001;107:255-64.
38. Pruefer D, Scalia R, Lefer AM. Homocysteine provokes leukocyte-endothelium interaction by downregulation of nitric oxide. Gen Pharmacol 1999;33:487-98.
39. Anderson TJ, Meredith IT, Charboneau F, Yeung AC, Frei B, Selwyn AP, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996;93:1647-50.
40. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med 2002;346:1954-62.
41. Signorelli SS, Neri S, Di Pino L, Costa MP, Pennisi G, Digrandi D, et al. Oxidative stress and endothelial damage in patients with asymptomatic carotid atherosclerosis. Clin. Exp Med 2001;1:9-12.
42. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993;91:29-37.
43. Steinberg D, Parthasarathy S, Carew T. Beyond cholesterol: Modifications of low density lipoproteins that increase its atherogenicity. N Engl J Med 1989;320:915-29.
44. Ross R. Atherosclerosis, an inflammatory disease. N Engl J Med 1999;340:115-26.
45. Steinbrecher UP. Receptors for oxidized low density lipoprotein. Biochim Biophys Acta 1999;1436:279-98.
46. Gillotte K, Hörkkö S, Witztum JL, Steinberg D. Oxidized phospholipids, linked to apolipoprotein B of oxidized LDL, are ligands for macrophage scavenger receptors. J Lipid Res 2000;41:824-33.
47. Mehta JL, Li D. Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. J Am Coll Cardiol 2002;39:1429-35.
48. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med 2001;11:142-7.
49. Cracowski JL, Devillier P, Durand T, Stanke-Labesque F, Bessard G. Vascular biology of the isoprostanes. J Vasc Res 2001;38:93-103.
50. Chisolm GM, Steinberg D. The oxidative hypothesis of atherogenesis: An overview. Free Radic Biol Med 2000;28:1815-26.
51. Patel RP, Moellering D, Murphy-Ullrich J, Jo H, Beckman JS, Darley-Usmar VM. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. Free Radic Biol Med 2000;28:1780-94.
52. Leonarduzzi G, Arkan MC, Basaga H, Chiarpotto E, Sevanian A, Poli G. Lipid oxidation products in cell signaling. Free Radic Biol Med 2000;28:1370-8.
53. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999;10:245-57.
54. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Ciculation 2000;101:2411-7.
55. Delbosc S, Cristol JP, Descomps B, Chénard J, Sirois P. De l'oxygène à l'anion superoxyde, Peut-on moduler la NADPH oxydase? J Soc Biol 2001;19:401-11.